MYCN and neuroblastoma: To address this knowledge gap, we performed untargeted metabolomics (Metabolon Inc., Discovery HD4TM platform) in two NB cell lines with perturbed MYCN expression (LAN5 shMYCN and MYCN3 Tet-On) and NB primary tumors (MYCN-amplified [MNA] n = 18; non MYCN-amplified [non MNA] n = 18, Supplementary Data 1).